Evidence map›Paper›PMID 26704434›Full record

ArticleNeuroscience letters2016

Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.

Jillienne C Touchette, Julie M Breckenridge, Gerald H Wilken, Heather Macarthur

Abstract read
In one paragraph

Article in Neuroscience letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.Movement disorders : official journal of the Movement Disorder Society · 2019
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jillienne C TouchetteDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 S Grand Blvd, St. Louis, MO 63104, United States.
Julie M BreckenridgeDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 S Grand Blvd, St. Louis, MO 63104, United States.
Gerald H WilkenDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 S Grand Blvd, St. Louis, MO 63104, United States.
Heather MacarthurDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 S Grand Blvd, St. Louis, MO 63104, United States. Electronic address: macarthu@slu.edu.
Saint Louis University · US

Funding

Pharmacological Sciences Training GrantT32GM008306 · NIGMS · SAINT LOUIS UNIVERSITY · PI EGAN, TERRANCE M, WALKER, JOHN K. · 1990 to 2020
$3.6M
NIGMS NIH HHS T32 GM008306PHS HHS NIGMS008306
6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by progressive neurodegeneration of nigrastriatal dopaminergic neurons leading to clinical motor dysfunctions. Many animal models of PD have been developed using exogenous neurotoxins and pesticides. Evidence strongly indicates that the dopaminergic neurons of the substantia nigra pars compacta (SNpc) are highly susceptible to neurodegeneration due to a number of factors including oxidative stress and mitochondrial dysfunction. Oxidation of DA to a potential endogenous neurotoxin, dopaminochrome (DAC), may be a potential contributor to the vulnerability of the nigrostriatal tract to oxidative insult. In this study, we show that DAC causes slow and progressive degeneration of dopaminergic neurons in contrast to 1-methyl-4-phenylpyridinium (MPP(+)), which induces rapid lesions of the region. The DAC model may be more reflective of early stresses that initiate the progressive neurodegenerative process of PD, and may prove a useful model for future neurodegenerative studies.

Indexed as

1-Methyl-4-phenylpyridiniumAnimalsDisease Models, AnimalDopaminergic NeuronsIndolequinonesMaleNerve DegenerationParkinson DiseasePars CompactaRats, Sprague-Dawley1-Methyl-4-phenylpyridiniumaminochrome 1IndolequinonesDopamineNeurodegenerationOxidationParkinson’s diseaseSubstantia nigra pars compacta

Identifiers

PMID26704434
PMCPMC4728017
OpenAlexW2209577647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.